Evidence map›Paper›PMID 34691256›Full record

ArticleOncology letters2021

Role of uromodulin and complement activation in the progression of kidney disease.

Fei Shen, Maojing Liu, Fei Pei, Li Yu, Xiangdong Yang

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Fei ShenDepartment of Nephrology, Qi Lu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Maojing LiuDepartment of Nephrology, Qi Lu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Fei PeiDepartment of Nephrology, Qi Lu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Li YuDepartment of Nephrology, Qi Lu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Xiangdong YangDepartment of Nephrology, Qi Lu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uromodulin (UMOD) is a glycoprotein that is selectively expressed on the epithelial cells of the thick ascending limb of Henle's loop and the early distal renal tubule. The present study aimed to investigate whether UMOD was associated with complement activation in patients with renal diseases. In addition, its biological function was examined

Indexed as

complement componentsIgA nephropathylupus nephritisuromodulin

Identifiers

PMID34691256
PMCPMC8527566
OpenAlexW3205865897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.